secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001549595-23-000053
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused
--------------------------------------------------------------------------------

- FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.
- Patients currently enrolled who derive clinical benefit may continue treatment per ongoing protocol.
- Hold follows Nurix's communication to FDA of intention to transition to an improved manufacturing process.
- Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/0001549595-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959523000053/nrix-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001549595-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer